Drug Cocktail

Phase 1Small molecule

Drug Cocktail is one of 21 small molecule programs targeting Prostatic Neoplasms, Castration-Resistant. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostatic Neoplasms, Castration-ResistantActive, not recruiting

Drug InteractionsRecruiting

Prostatic Neoplasms, Castration-ResistantPhase 1

Active, not recruiting

Drug InteractionsPhase 1

Recruiting

Competition

Competitive Landscape

14 competitors in Prostatic Neoplasms, Castration-Resistant

#DrugCompanyPhaseTrials

Taxotere

AAvyxa

Phase 3

2 2

Zytiga

Johnson & Johnson

Phase 2

2 3

Rayos

RRoxane Laboratories

Phase 2

3 4

Zejula

GGlaxo Dba Glaxosmithkline

Phase 2

1 5

Pasritamig

Johnson & Johnson

Phase 3

1 6

Cetrelimab

Johnson & Johnson

Phase 2

1 7

Actos

Takeda

Phase 1

1 8

Crestor

AstraZeneca

Phase 1

1 9

Jevtana

Sanofi

Preclinical

1 10

Lynparza

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT02592317

Clinical

Trials by Indication[1]

Psoriasis2 trials

A Study of Ixekizumab in Participants With Plaque Psoriasis

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02993471·28 enrolled

A Study of Mirikizumab in Participants With Plaque Psoriasis

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT03718884·29 enrolled

Drug Interactions1 trial

Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach

Recruiting·WWashington State University·Phase 1·NCT06693960·16 enrolled

Abemaciclib1 trial

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02688088·48 enrolled

Drug1 trial

Effects of Repeated Doses of Foliglurax on Drug Metabolizing Enzymes in Healthy Subjects

Completed· Lundbeck logo

Lundbeck·Phase 1·NCT04275115·20 enrolled

Metastatic Melanoma1 trial

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Completed· Roche logo

Roche·Phase 1·NCT01001299·25 enrolled

1 more indication

Prostatic Neoplasms, Castration-Resistant1 trial

Drug-drug Interaction Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Subjects With Castration-Resistant Prostate Cancer

Active, not recruiting·AAragon Pharmaceuticals, Inc.·Phase 1·NCT02592317·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Drug Cocktail. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug Cocktail compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug Cocktail. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eli Lilly

Drug Cocktail

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Psoriasis2 trials

Drug Interactions1 trial

Abemaciclib1 trial

Drug1 trial

Metastatic Melanoma1 trial

Prostatic Neoplasms, Castration-Resistant1 trial

References

Drug Info

Quick Facts

Related News